Clinical value of continuous administration of sorafenib in combination with modified transarterial chemoembolization in patients with unresectable hepatocellular carcinoma

Chin Med J (Engl). 2013 Jan;126(2):385-6.

Authors

Yong-Hui Huang¹, Wei Chen, Jia-Ping Li, Bin Chen, Jian-Yong Yang

Affiliation

¹ Department of Interventional Radiology, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, China.

PMID: 23324295

No abstract available

MeSH terms

Aged
Aged, 80 and over
Antineoplastic Agents / therapeutic use*
Carcinoma, Hepatocellular / mortality
Carcinoma, Hepatocellular / therapy*
Chemoembolization, Therapeutic*
Combined Modality Therapy
Disease-Free Survival
Humans
Liver Neoplasms / mortality
Liver Neoplasms / therapy*
Middle Aged
Niacinamide / analogs & derivatives*
Niacinamide / therapeutic use
Phenylurea Compounds / therapeutic use*
Sorafenib

Substances

Antineoplastic Agents
Phenylurea Compounds
Niacinamide
Sorafenib